VAXXINITY INC. news, videos and press releases
For more news please use our advanced search feature.
VAXXINITY INC. - More news...
VAXXINITY INC. - More news...
- Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
- Vaxxinity Issues Shareholder Letter
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
- Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
- Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
- Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
- Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
- Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
- Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
- Vaxxinity to Present at Upcoming November Medical and Investor Conferences
- Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Vaxxinity to Present at Upcoming Investor Conferences in September
- Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
- Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
- Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
- Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
- Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
- Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
- Vaxxinity Joins TransCelerate Research and Development Consortium
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
- Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
- Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
- Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
- Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
- Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Vaxxinity to Present at Upcoming Investor Conferences in November
